Sentinel lymph node biopsy for breast cancer: How many nodes are enough?

Shaheen Zakaria, Amy C Degnim, Celina G. Kleer, Kathleen A. Diehl, Vincent M. Cimmino, Alfred E. Chang, Lisa A. Newman, Michael S. Sabel

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Introduction: Sentinel lymph node (SLN) biopsy using blue dye and radioisotope often results in the removal of multiple SLNs. We sought to determine whether there is a point where the surgeon can terminate the procedure without sacrificing accuracy. Methods: One thousand one hundred ninety-seven patients from University of Michigan and the Mayo Clinic undergoing SLN biopsy formed the study population. Surgeons removed all SLNs until counts within the axilla were less than 10% of the highest node ex vivo and recorded the order in which they were removed. Results: The mean number of SLNs removed per patient was 2.5 (range 1-9). Approximately 42% of patients had three or more lymph nodes removed, while 19% had four or more lymph nodes removed. Eighteen percent of patients (132/725) at University of Michigan and 22% (103/472) at Mayo Clinic had a positive SLN. Ninety-eight percent (231/235) of patients with lymph node metastases were identified by the 3rd SLN while 100% were identified by the 4th SLN. Conclusion: Among patients undergoing SLN biopsy for breast cancer, the only positive SLN is rarely identified in the 4th or higher node. Terminating the procedure at the 4th node may lower the cost of the procedure and reduce morbidity.

Original languageEnglish (US)
Pages (from-to)554-559
Number of pages6
JournalJournal of Surgical Oncology
Volume96
Issue number7
DOIs
StatePublished - Dec 1 2007

Fingerprint

Sentinel Lymph Node Biopsy
Breast Neoplasms
Lymph Nodes
Axilla
Radioisotopes
Coloring Agents
Neoplasm Metastasis
Morbidity
Costs and Cost Analysis
Sentinel Lymph Node
Population

Keywords

  • Breast cancer
  • Lymph nodes
  • Node biopsy
  • Sentinel lymph

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Zakaria, S., Degnim, A. C., Kleer, C. G., Diehl, K. A., Cimmino, V. M., Chang, A. E., ... Sabel, M. S. (2007). Sentinel lymph node biopsy for breast cancer: How many nodes are enough? Journal of Surgical Oncology, 96(7), 554-559. https://doi.org/10.1002/jso.20878

Sentinel lymph node biopsy for breast cancer : How many nodes are enough? / Zakaria, Shaheen; Degnim, Amy C; Kleer, Celina G.; Diehl, Kathleen A.; Cimmino, Vincent M.; Chang, Alfred E.; Newman, Lisa A.; Sabel, Michael S.

In: Journal of Surgical Oncology, Vol. 96, No. 7, 01.12.2007, p. 554-559.

Research output: Contribution to journalArticle

Zakaria, S, Degnim, AC, Kleer, CG, Diehl, KA, Cimmino, VM, Chang, AE, Newman, LA & Sabel, MS 2007, 'Sentinel lymph node biopsy for breast cancer: How many nodes are enough?', Journal of Surgical Oncology, vol. 96, no. 7, pp. 554-559. https://doi.org/10.1002/jso.20878
Zakaria, Shaheen ; Degnim, Amy C ; Kleer, Celina G. ; Diehl, Kathleen A. ; Cimmino, Vincent M. ; Chang, Alfred E. ; Newman, Lisa A. ; Sabel, Michael S. / Sentinel lymph node biopsy for breast cancer : How many nodes are enough?. In: Journal of Surgical Oncology. 2007 ; Vol. 96, No. 7. pp. 554-559.
@article{bf8ef07f9dee4071be923e5802c00769,
title = "Sentinel lymph node biopsy for breast cancer: How many nodes are enough?",
abstract = "Introduction: Sentinel lymph node (SLN) biopsy using blue dye and radioisotope often results in the removal of multiple SLNs. We sought to determine whether there is a point where the surgeon can terminate the procedure without sacrificing accuracy. Methods: One thousand one hundred ninety-seven patients from University of Michigan and the Mayo Clinic undergoing SLN biopsy formed the study population. Surgeons removed all SLNs until counts within the axilla were less than 10{\%} of the highest node ex vivo and recorded the order in which they were removed. Results: The mean number of SLNs removed per patient was 2.5 (range 1-9). Approximately 42{\%} of patients had three or more lymph nodes removed, while 19{\%} had four or more lymph nodes removed. Eighteen percent of patients (132/725) at University of Michigan and 22{\%} (103/472) at Mayo Clinic had a positive SLN. Ninety-eight percent (231/235) of patients with lymph node metastases were identified by the 3rd SLN while 100{\%} were identified by the 4th SLN. Conclusion: Among patients undergoing SLN biopsy for breast cancer, the only positive SLN is rarely identified in the 4th or higher node. Terminating the procedure at the 4th node may lower the cost of the procedure and reduce morbidity.",
keywords = "Breast cancer, Lymph nodes, Node biopsy, Sentinel lymph",
author = "Shaheen Zakaria and Degnim, {Amy C} and Kleer, {Celina G.} and Diehl, {Kathleen A.} and Cimmino, {Vincent M.} and Chang, {Alfred E.} and Newman, {Lisa A.} and Sabel, {Michael S.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1002/jso.20878",
language = "English (US)",
volume = "96",
pages = "554--559",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Sentinel lymph node biopsy for breast cancer

T2 - How many nodes are enough?

AU - Zakaria, Shaheen

AU - Degnim, Amy C

AU - Kleer, Celina G.

AU - Diehl, Kathleen A.

AU - Cimmino, Vincent M.

AU - Chang, Alfred E.

AU - Newman, Lisa A.

AU - Sabel, Michael S.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Introduction: Sentinel lymph node (SLN) biopsy using blue dye and radioisotope often results in the removal of multiple SLNs. We sought to determine whether there is a point where the surgeon can terminate the procedure without sacrificing accuracy. Methods: One thousand one hundred ninety-seven patients from University of Michigan and the Mayo Clinic undergoing SLN biopsy formed the study population. Surgeons removed all SLNs until counts within the axilla were less than 10% of the highest node ex vivo and recorded the order in which they were removed. Results: The mean number of SLNs removed per patient was 2.5 (range 1-9). Approximately 42% of patients had three or more lymph nodes removed, while 19% had four or more lymph nodes removed. Eighteen percent of patients (132/725) at University of Michigan and 22% (103/472) at Mayo Clinic had a positive SLN. Ninety-eight percent (231/235) of patients with lymph node metastases were identified by the 3rd SLN while 100% were identified by the 4th SLN. Conclusion: Among patients undergoing SLN biopsy for breast cancer, the only positive SLN is rarely identified in the 4th or higher node. Terminating the procedure at the 4th node may lower the cost of the procedure and reduce morbidity.

AB - Introduction: Sentinel lymph node (SLN) biopsy using blue dye and radioisotope often results in the removal of multiple SLNs. We sought to determine whether there is a point where the surgeon can terminate the procedure without sacrificing accuracy. Methods: One thousand one hundred ninety-seven patients from University of Michigan and the Mayo Clinic undergoing SLN biopsy formed the study population. Surgeons removed all SLNs until counts within the axilla were less than 10% of the highest node ex vivo and recorded the order in which they were removed. Results: The mean number of SLNs removed per patient was 2.5 (range 1-9). Approximately 42% of patients had three or more lymph nodes removed, while 19% had four or more lymph nodes removed. Eighteen percent of patients (132/725) at University of Michigan and 22% (103/472) at Mayo Clinic had a positive SLN. Ninety-eight percent (231/235) of patients with lymph node metastases were identified by the 3rd SLN while 100% were identified by the 4th SLN. Conclusion: Among patients undergoing SLN biopsy for breast cancer, the only positive SLN is rarely identified in the 4th or higher node. Terminating the procedure at the 4th node may lower the cost of the procedure and reduce morbidity.

KW - Breast cancer

KW - Lymph nodes

KW - Node biopsy

KW - Sentinel lymph

UR - http://www.scopus.com/inward/record.url?scp=36549034778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549034778&partnerID=8YFLogxK

U2 - 10.1002/jso.20878

DO - 10.1002/jso.20878

M3 - Article

C2 - 17685432

AN - SCOPUS:36549034778

VL - 96

SP - 554

EP - 559

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 7

ER -